Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events.

Terpos E. et al, (2025), Am j hematol

Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma.

Tsang C. et al, (2025), Bmc cancer, 25

Belantamab Mafodotin Monotherapy for Multiply-Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland.

Watson ECR. et al, (2025), Ejhaem, 6

Dysregulated immune proteins in plasma in the UK Biobank predict Multiple Myeloma 12 years before clinical diagnosis.

Fieggen J. et al, (2025), Blood adv

Erratum: Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.

Perrot A. et al, (2025), J clin oncol, 43

Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach.

Kannan A. et al, (2025), Blood rev

Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.

Perrot A. et al, (2025), Eur j haematol

Diagnosis and management of monoclonal gammopathy of renal significance: A British Society for Haematology good practice paper.

Pinney J. et al, (2025), Br j haematol

Approaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?

Vijjhalwar R. et al, (2025), Indian journal of hematology and blood transfusion

Castleman disease.

Qasim J. and Ramasamy K., (2025), Reumatologia, 63, 141 - 143

Multiple myeloma

Ramasamy K. and Lonial S., (2025), Hoffbrand S Postgraduate Haematology Eighth Edition, 524 - 546

Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.

Ramasamy K. et al, (2024), Clin lymphoma myeloma leuk

The UK consensus supporting effective introduction of novel treatments for multiple myeloma in the National Health Service.

Popat R. et al, (2024), Ejhaem, 5, 1133 - 1143

Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and UK Myeloma Society Good Practice Paper.

Kaiser M. et al, (2024), Br j haematol

Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil

Hungria V. et al, (2024), Cancers, 16

Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma.

Agarwal G. et al, (2024), Haematologica, 109, 1960 - 1965

Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.

Lee HC. et al, (2024), Eur j haematol

Challenges in designing and running smouldering myeloma interventional clinical trials.

Lecat C. et al, (2024), Ejhaem, 5, 418 - 420

Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination.

Twumasi C. et al, (2024), Eur j haematol, 112, 547 - 553

Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.

Ramasamy K. et al, (2024), Haematologica

Load More

Include forthcoming?